Mepolizumab biosimilar (CTTQ Pharma)

美泊利单抗生物类似药（正大天晴）

Report date: 2025/03/26 16:55:32

Base Information

Drug NameMepolizumab biosimilar (CTTQ Pharma)
Drug Alias Name美泊利珠单抗美泊珠单抗TQC3566TQC-3566
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsLymphohistiocytosis, HemophagocyticHypereosinophilic SyndromeEosinophilic Granulomatosis With Polyangiitis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsHypereosinophilic SyndromeEosinophilic Granulomatosis With PolyangiitisVasculitis +[7] 
Inactive IndicationsLymphohistiocytosis, HemophagocyticGranulomatosis with Polyangiitis

Other Information

ATC CodeN/A
Related LinksN/A